MMT-PLGA nanocomposites as an oral and controlled release carrier for 5 - Fluorouracil: A novel approach

International Journal of Pharmacy and Pharmaceutical Sciences

Volumn 5, Issue 2, 2013, Pages 332-341

  Seema, ^a   Datta, Monika ^a  

^a UNIVERSITY OF DELHI   (India)

Author keywords

5 Fluorouracil; Controlled release; Montmorillonite; Nanocomposites; Oral chemotherapy

Indexed keywords

FLUOROURACIL; NANOCOMPOSITE;

ARTICLE; CALIBRATION; CONTROLLED RELEASE FORMULATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; DRUG SYNTHESIS; GRAVIMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NANOENCAPSULATION; PARTICLE SIZE; SCANNING ELECTRON MICROSCOPY; TRANSMISSION ELECTRON MICROSCOPY; X RAY DIFFRACTION;

EID: 84875945717     PISSN: None     EISSN: 09751491     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. McCarron PA, Hall M. Incorporation of novel 1-alkylcarbonyloxymethyl prodrugs of 5-fluorouracil into poly (lactide-co-glycolide) nanoparticles. Int. J. Pharm 2008; 348: 115-124.
2. Yuasa H, Matsuda K, Gu J, Suzuki E, Yokouchi I. and Watanabe J. Dose-dependent gastrointestinal absorption of 5-fluorouracil in rats in vivo. Biol. Pharm. Bull.1996; 19: 1494-1498.
3. Rejinold NS, Muthunarayanan M, Chennazhi KP, Nair SV and Jayakumar R. 5-Fluorouracil loaded fibrinogen nanoparticles for cancer drug delivery applications. Int. J. Biol. Macromol. 2011; 48: 98-105.
4. H.J. Schmoll, T. Buchele, A. Grothey, W. Dempke, "Where do we stand with 5-fluorouracil?", Semin Oncol.1999; 26: 589-605.
5. Uhrich EK, Langer RS, Cannizzaro SM and Shakesheff KM. Polymeric systems for controlled drug release, Chem. Rev.1999; 99: 3181-3198.
6. Viseras C, Aguzzi C, Cerezo P and Caramella C. Use of clays as drug delivery systems: Possibilities and limitations. Appl. Clay Sci. 2007; 36: 22-36.
7. Suresh R, Borkar SN, Sawant VA, Shende VS and Dimble SK. Nanoclay drug delivery system. Int. J. Pharm. Sci. and Nanotech. 2010; 3, suppl 2: 901-905.
8. Wang X, Yumin Du and Jiwen Luo, Biopolymer/montmorillonite nanocomposite: preparation, drug-controlled release property and cytotoxicity. Nanotechnology. 2008; 19: 06570.
9. Depan D, Kumar AP and Singh RP. Cell proliferation and controlled drug release studies of nanohybrids based on chitosan-g-lactic acid and montmorillonite. Acta Biomaterialia. 2009; 5: 93-100.
10. Iliescu RI, Andronescu E, Voicu G, Ficai A and Covaliu CI. Hybrid materials based on montmorillonite and citostatic drugs: Preparation and characterization. Appl. Clay Sci.2011; 52: 62-68.
11. Chen Y, Zhou A, Bo Liu and Jun Liang. Tramadol hydrochloride/montmorillonite composite: Preparation and controlled drug release. Appl. Clay Sci. 2010; 49: suppl 3:108-112.
12. Nunes CD, Vaz PD, Fernandes AC, Ferreira P, Romao CC and Calhorda M.J. Loading and delivery of sertraline using inorganic micro and mesoporous materials. Eur. J. Pharm. Biopharm 2007; 66:357-365.
13. Joshi GV, Patel HA, Kevadiya BD and Bajaj HC. Montmorillonite intercalated with vitamin B1 as drug carrier. Appl. Clay Sci. 2009; 45: 248-253.
14. Seki Y and Yurdakoc K. Equilibrium, kinetics and thermodynamic aspects of Promethazine hydrochloride sorption by iron rich smectite. Colloids and Surfaces A: Physicochem. Eng. Aspects. 2009; 340:143-148.
15. Madurai SL, Joseph SW, Mandal AB, Tsibouklis J and Reddy B.S. Intestine-Specific, Oral delivery of captopril/montmorillonite: formulation and release kinetics. Nanoscale Research Letters, 2011; 6:suppl 15.
16. Lee YH, Kuo TF, Chen BY, Yi-Kai Feng, Yu-Ren Wen, Wu-Ching Lin and Lin FH, Toxicity assessment of montmorillonite as a drug carrier for pharmaceutical applications: yeast and rats model. Biomedical Engineering Applications, Basis & Communications, 2005; 17: 72-78.
17. Feng SS, Mei L, Anitha P, Gan CW and Zhou W. Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel. Biomaterials, 2009; 30:3297-3306.
18. Dong Y and Feng SS. Poly (D, L-lactide-co-glycolide)/montmorillonite nanoparticles fororal delivery of anticancer drugs. Biomaterials, 2005; 26: 6068-6076.
19. Kevadiya BD, Patel TA, Thumbar RP, Pandya MP and Bajaj HC. Layered inorganic nanocomposites: A promising carrier for 5-fluorouracil,. Eur. J. Pharm. Biopharm.2012; 81: 91-101.
20. Lin FH, Lee YH, Jian CH, Jau-Min Wong, Ming-Jium Shieh, Cheng-Yi Wang, A study of purified montmorillonite intercalated with 5-fluorouracil as drug carrier. Biomaterials. 2002, 23: 1981-87.
21. Huang L, Mei L, Yan F, Zhang C and Zheng Y, The Effect of Poloxamer 188 on nanoparticle Morphology, Size, Cancer Cell Uptake, and Cytotoxicity. Nanotechnology, Biology and Medicine, 2010; 6:170-178.
22. Nair LK, Jagadeeshan S, Nair SA, Kumar GSV. Biological evaluation of 5-fluorouracil nanoparticles for cancer chemotherapy and its dependence on the carrier, PLGA. Int. J. Nanomedicine.2011; 6: 1685-1697.
23. Nagarwal RC, Singh PN, Shri Kant, Maiti P, and Pandit JK. Chitosan nanoparticles of 5-fluorouracil for ophthalmic delivery: characterization, in-vitro and in-vivo study. Chem. Pharm. Bull. 2011, 59 suppl 2: 272-278.
24. Schmolka IR. A review of block polymer surfactants. J. of American Oil Chemists' society, 1977; 54: 110-116.
25. Saski W, Shah SG. Availability of drugs in the presence of surface-active agents I critical micelle concentrations of some oxyethylene oxypropylene polymer, J. Pharm. Sci. 1965; 54 suppl 1: 71-74.
26. Zhang Y, Li J, Lang M, Tang X, Li L and Shen X. Folate-functionalized nanoparticles for controlled 5-Fluorouracil delivery. J. Colloid Interface Sci. 2011; 354: 202-209.
27. Das PR, Nanda RM, Behara A and Nayak PL. Gelatin blended with nanoparticle cloisite30B (MMT)for control drug delivery of anticancer drug paclitaxel. Int. Res. J. Biochem. and Bioinform. 2011; 1 suppl 2: 35-42.
28. Xie J, Tan JC, and Wang CH. Biodegradable films developed by electrospray deposition for sustained drug delivery. J. Pharm. Sci.; 2008, 97suppl 8: 3109-3122.
29. sted. India: Intech, 2011, p. 113-138 ISBN: 978-953-307-202-9
30. Zampori L, Stampino PG, Cristiani C, Cazzola P and Dotelli G. Intercalation of poly(ethylene-oxides) in montmorillonite: tailor-made nanocontainers for drug delivery systems. Appl. Clay Sci. 2010;50:, 266-270.
31. Lee JS, Chae GS, Kun An T, and Khang G. Preparation of 5-fluorouracil-loaded poly(l-lactide-co-glycolide) wafer and evaluation of in vitro release behaviour. Macromol. Res.; 2003, 11 suppl 3: 183-188.
32. Kalaria DR, Sharma G, Beniwal V and Ravi Kumar MNV. Design of biodegradable nanoparticles for oral delivery of doxorubicin: in vivo pharmacokinetics and toxicity studies in rats. Pharm. Res.; 2009, 26 suppl 3: 492-501.
33. Win KY, Feng SS. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterial; 2005; 26: 2713-2722.
34. Puoci F, Iemma F, Cirillo G, Picci N, Matricardi P and Alhaique F. Molecularly Imprinted Polymers for 5-Fluorouracil Release in Biological Fluids, Molecules; 2007, 12: 805-814.